- Home
- CVR vs INAB Comparison
CVR vs INAB Comparison
Compare CVR & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- INAB
- Stock Information
- Founded
- CVR 1920
- INAB 2016
- Country
- CVR United States
- INAB United States
- Employees
- CVR N/A
- INAB N/A
- Industry
- CVR Industrial Machinery/Components
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- CVR Industrials
- INAB Health Care
- Exchange
- CVR Nasdaq
- INAB Nasdaq
- Market Cap
- CVR 9.5M
- INAB 10.6M
- IPO Year
- CVR N/A
- INAB 2021
- Fundamental
- Price
- CVR $9.40
- INAB $1.88
- Analyst Decision
- CVR
- INAB Strong Buy
- Analyst Count
- CVR 0
- INAB 2
- Target Price
- CVR N/A
- INAB $108.00
- AVG Volume (30 Days)
- CVR 2.2K
- INAB 64.5K
- Earning Date
- CVR 11-11-2025
- INAB 11-10-2025
- Dividend Yield
- CVR 1.33%
- INAB N/A
- EPS Growth
- CVR N/A
- INAB N/A
- EPS
- CVR N/A
- INAB N/A
- Revenue
- CVR $25,617,681.00
- INAB N/A
- Revenue This Year
- CVR N/A
- INAB N/A
- Revenue Next Year
- CVR N/A
- INAB N/A
- P/E Ratio
- CVR N/A
- INAB N/A
- Revenue Growth
- CVR N/A
- INAB N/A
- 52 Week Low
- CVR $8.15
- INAB $1.82
- 52 Week High
- CVR $22.27
- INAB $12.53
- Technical
- Relative Strength Index (RSI)
- CVR 40.86
- INAB 32.98
- Support Level
- CVR $9.40
- INAB $2.04
- Resistance Level
- CVR $9.75
- INAB $2.15
- Average True Range (ATR)
- CVR 0.23
- INAB 0.10
- MACD
- CVR -0.00
- INAB -0.02
- Stochastic Oscillator
- CVR 35.85
- INAB 18.27
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.